Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Half of readers call for MURs to be scrapped

Some 45% of respondents to a C+D poll say medicines use reviews are "no longer fit for purpose"

EXCLUSIVE

Almost half of pharmacy professionals feel there is no way to reduce inappropriate MURs other than to scrap the service, a C+D poll has revealed.

Some 45% of 320 respondents to the poll, which ran on the C+D website from April 14-20, agreed the service is "not fit for purpose".

The results come in the wake of allegations made by the Guardian earlier this month that Boots pressures its pharmacists to carry out unnecessary MURs for profit – a claim the multiple told C+D it “doesn’t recognise”.

The remaining 55% of respondents to C+D's poll were evenly split on alternative ways to prevent inappropriate MURs, with 19% opting for reducing or removing payments for delivering the service.

Another 18% called for stronger regulation from the General Pharmaceutical Council (GPhC), while the same proportion said pharmacists need condition-specific guidelines on how to carry out MURs.

Twitter response: Scrap or salvage?

Pharmacists shared their views on the service's future during C+D's Twitter debate last week (April 22).

This is the latest in a series of articles exploring the issue of MUR abuse, following on from our Twitter debate. We'll be sharing more exclusive data on the profession's view on MURs, and coverage of the debate, throughout the week. 

How could the MUR service be improved?

Related Content

Topics


         
Pharmacist
Yeovil, Winchester & Dorchester
£50-55,000 per annum

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD008098

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel